Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Download these expert-selected slides on treating patients with AML with targetable biomarkers
Amir T. Fathi, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.23 MB
Released: December 10, 2021


Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Bristol-Myers Squibb
Genentech, a member of the Roche Group

Related Content

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in biomarker testing for optimal management of advanced NSCLC

Zofia Piotrowska, MD, MHS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 27, 2022 Expired: May 26, 2023

Commentary on current molecular testing and biomarker-guided care in NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Released: May 26, 2022

Dr. Robin L. Jones offers expert commentary on TKI therapy in advanced osteosarcoma and nonadipocytic sarcoma, from Clinical Care Options (CCO)

Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: May 25, 2022

A video on providing respectful healthcare for transgender persons as illustrated through the personal transition story of Pharmacist Olivia Buckoski, from Clinical Care Options (CCO)

Olivia Buckoski, PharmD Released: May 25, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings